{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:27:21Z","timestamp":1777418841640,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To describe the evidence assessing the use of anti-thrombin III (AT-III) in the management of toxicity associated with hematopoietic stem-cell transplantation (HSCT)\u2014conditioning regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Clinical literature was accessed through conference proceedings, EMBASE, the Cochrane database, and MEDLINE (1966-December 2003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>Case reports, small case series, case\u2014control and cohort studies, and randomized controlled trials of AT-III in HSCT were evaluated. Publications examining AT-III use in the non-HSCT setting were also explored. Key search terms included AT-III, transplantation, and veno-occlusive disease (VOD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Severe VOD and ensuing multiple organ dysfunction is associated with high mortality in HSCT. A low AT-III level has been shown to correlate with the development of organ dysfunction. Phase II trials, case series, and one small, randomized, placebo-controlled study suggest a benefit when AT-III therapy is instituted early in the course of VOD\/multiple organ dysfunction syndrome. In all of these reports, AT-III use was devoid of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Although further studies are needed to ascertain the optimal target level, method, and duration of administration, AT-III is still a viable alternative for the treatment of severe VOD and ensuing multiple organ dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d235","type":"journal-article","created":{"date-parts":[[2004,5,3]],"date-time":"2004-05-03T20:28:41Z","timestamp":1083616121000},"page":"1053-1059","source":"Crossref","is-referenced-by-count":13,"title":["Anti-Thrombin III in the Management of Hematopoietic Stem-Cell           Transplantation\u2014Associated Toxicity"],"prefix":"10.1177","volume":"38","author":[{"given":"Rami B","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Rami B Ibrahim MSc PharmD BCPS BCOP, Clinical Pharmacy Specialist\r            (Hematology\/Oncology), Karmanos Cancer Institute, Harper University Hospital, The\r            Detroit Medical Center, Detroit, MI; Adjunct-Assistant Professor, Pharmacy Practice,\r            Eugene Applebaum College of Pharmacy and Allied Health Professions, Wayne State\r            University, Detroit"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Peres","sequence":"additional","affiliation":[{"name":"Edward Peres MD, Pediatric Hematology\/Oncology Fellow, Karmanos Cancer\r            Institute, Children Hospital of Michigan, Wayne State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Dansey","sequence":"additional","affiliation":[{"name":"Roger Dansey MD, Bone Marrow Transplantation Service, Karmanos Cancer\r            Institute; Associate Professor of Medicine, School of Medicine, Wayne State\r            University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneer H","family":"Abidi","sequence":"additional","affiliation":[{"name":"Muneer H Abidi MD, Bone Marrow Transplantation Service, Karmanos Cancer\r            Institute; Associate Professor of Medicine, School of Medicine, Wayne State\r            University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban M","family":"Abella","sequence":"additional","affiliation":[{"name":"Esteban M Abella MD, Bone Marrow Transplantation Service, Karmanos\r            Cancer Institute; Associate Professor of Medicine and Pediatrics, School of Medicine,\r            Wayne State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Klein","sequence":"additional","affiliation":[{"name":"Jared Klein MD, Bone Marrow Transplantation Service, Karmanos Cancer\r            Institute; Associate Professor of Medicine, School of Medicine, Wayne State\r            University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,6,1]]},"reference":[{"key":"bibr1-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.14.1558"},{"key":"bibr2-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199403243301206"},{"key":"bibr3-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1009909"},{"key":"bibr4-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200003000-00001"},{"key":"bibr5-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10220"},{"key":"bibr6-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01680.x"},{"key":"bibr7-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0255"},{"key":"bibr8-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840040121"},{"key":"bibr9-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"bibr10-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200001150-00030"},{"key":"bibr11-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03561-3"},{"key":"bibr12-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702082"},{"key":"bibr13-aph.1D235","first-page":"495","volume":"14","author":"Pettitt AR","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"bibr14-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200205001-00014"},{"key":"bibr15-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-996141"},{"key":"bibr16-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(03)00002-X"},{"key":"bibr17-aph.1D235","doi-asserted-by":"publisher","DOI":"10.4065\/78.5.589"},{"key":"bibr18-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(00)00269-3"},{"key":"bibr19-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530160041031"},{"key":"bibr20-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701225"},{"key":"bibr21-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701445"},{"key":"bibr22-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1177\/107602960200800207"},{"key":"bibr23-aph.1D235","first-page":"549","volume":"127","author":"Shulman HM","year":"1987","journal-title":"Am J Pathol"},{"key":"bibr24-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834"},{"key":"bibr25-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199604150-00014"},{"key":"bibr26-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1378\/chest.104.3.882"},{"key":"bibr27-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00004630-200021020-00007"},{"key":"bibr28-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200009001-00009"},{"key":"bibr29-aph.1D235","first-page":"505","volume":"15","author":"Haire WD","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"bibr30-aph.1D235","first-page":"443","volume":"17","author":"Patton DF","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"bibr31-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06951.x"},{"key":"bibr32-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700985"},{"key":"bibr33-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.10.2458.2458"},{"key":"bibr34-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(98)50003-1"},{"key":"bibr35-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(89)90135-7"},{"key":"bibr36-aph.1D235","first-page":"191a","volume":"1","author":"Peres E","year":"2001","journal-title":"Early intervention with antithrombin III is effective in the prevention of progression and treatment of hepatic veno-occlusive disease (abstract 801)"},{"key":"bibr37-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1007\/PL00014344"},{"key":"bibr38-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)00947-0"},{"key":"bibr39-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.15.1869"},{"key":"bibr40-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703618"},{"key":"bibr41-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1216"},{"key":"bibr42-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702854"},{"key":"bibr43-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704087"},{"key":"bibr44-aph.1D235","first-page":"706a","volume":"1","author":"Yannaki E","year":"2003","journal-title":"Fresh frozen plasma during conditioning in addition to heparin, has possible beneficial effect in veno-occlusive disease prophylaxis (abstract 2613)"},{"key":"bibr45-aph.1D235","first-page":"710a","volume":"1","author":"Kim SE","year":"2003","journal-title":"Intravenous vs. oral busulfan\u2014conditioning therapy prior to allogeneic bone marrow transplantation\u2014a case controlled study (abstract 2629)"},{"key":"bibr46-aph.1D235","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00315.x"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D235","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:18Z","timestamp":1777374498000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["10.1345\/aph.1D235"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d235","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}